Vir Biotechnology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VIR research report →
Range $22 – $25
Price Chart
About the company
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus.
- CEO
- Marianne De Backer
- IPO
- 2019
- Employees
- 367
- HQ
- San Francisco, CA, US
Get TickerSpark's AI analysis on VIR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.44B
- P/E
- -7.10
- PEG
- -0.06
- P/S
- 5.02
- P/B
- 1.68
- EV/EBITDA
- -7.15
- Div Yield
- 0.00%
- Gross Margin
- 97.18%
- Op Margin
- -69.76%
- Net Margin
- -61.03%
- ROE
- -21.38%
- ROIC
- -20.30%
Latest fiscal year · YoY change
- Revenue
- $68.56M-7.6%
- Gross Profit
- $56.85M-3.3%
- Op Income
- $-468,020,000
- Net Income
- $-437,987,000+16.1%
- EPS
- $-3.16+17.5%
- OCF Growth
- +12.2%
- FCF Growth
- +12.6%
- 52W High
- $14.38
- 52W Low
- $5.45
- 50D MA
- $11.00
- 200D MA
- $9.80
- Beta
- 1.70
- RSI (14)
- 33
- Avg Volume
- 2.43M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Vir Biotechnology said Q3 was a pivotal quarter, with hepatitis delta Phase III data due soon, VIR-5500 moving toward registrational trials after proof of concept, and a new Gilead collaboration adding cash and external validation.· November 4, 2026
- ECLIPSE-1 topline data is expected this quarter, with ECLIPSE-2 and ECLIPSE-3 due in Q1 2027.
- Management said VIR-5500 achieved proof of concept with Astellas and also received FDA Fast Track designation in late-line mCRPC.
- The Gilead preclinical collaboration brought in $90 million upfront and could generate up to $1.74 billion more in milestones, plus royalties.
- Cash was $901 million at quarter-end, excluding the $90 million Gilead upfront received in October, and management said runway extends into the second half of 2028.
- Oncology progress was balanced by some caution: VIR-5818 remains ongoing after FDA feedback, and management said the dataset is not yet complete.
Vir reported third-quarter 2026 R&D expense of $80 million, down from $151 million a year ago, with the decline mainly due to a one-time $75 million milestone payment recognized in Q3 2025. SG&A was $24 million versus $22 million in the prior-year period, with the increase mainly from higher advisory and legal fees. The company ended Q3 with $901 million in cash, cash equivalents and investments, not including the $90 million from the Gilead collaboration received in October. Under the Gilead deal, Vir received $65 million upfront and a $25 million equity investment at a 30% premium, and it may receive up to $45 million in near-term preclinical milestones and up to $1.74 billion in additional milestones, plus tiered royalties. Management said current cash should fund operations into the second half of 2028.
Marianne De Backer framed the quarter as a turning point for both hepatitis delta and oncology, saying Vir is entering a “pivotal period” and is positioned for “meaningful value creation.” She emphasized that the hepatitis delta program could redefine the treatment paradigm if the ECLIPSE program confirms the deep viral suppression seen in Phase II, and she highlighted PRO-XTEN validation through both Astellas and Gilead. Her tone was confident but disciplined, repeatedly stressing capital selectivity, partnership strategy, and multiple near-term catalysts.
Aziz Sawaf focused on the financial flexibility created by the Gilead deal and on disciplined capital allocation. He said Vir received $90 million total under the collaboration, including $65 million upfront and a $25 million equity investment at a 30% premium, with no revenue share to Sanofi because the 20% pass-through has expired. On the quarter, he cited R&D of $80 million versus $151 million last year and SG&A of $24 million versus $22 million, and he said the $901 million cash balance supports operations into the second half of 2028, excluding the October Gilead cash receipt.
Analysts pressed on VIR-5500’s durability, proof-of-concept criteria, the timing and shape of upcoming pivotal trials, and whether Vir could share more detail on the FDA-aligned Phase III hepatitis delta endpoints and top-line package. Management declined to give updated VIR-5500 response data or specific proof-of-concept criteria, but said the designation was based on the totality of efficacy, safety, pharmacology and biomarker data. On HDV, management said ECLIPSE-1 will report the combined TND plus ALT endpoint and secondary TND data, while ECLIPSE-2 and ECLIPSE-3 use TND-only endpoints; it also said rapid enrollment in ECLIPSE-2 suggests meaningful unmet need and that ECLIPSE-3 compares monthly dosing against daily bulevirtide.
The call featured several concrete positives: near-term Phase III hepatitis delta readouts, a cash runway into the second half of 2028, and a new partnership with Gilead that validates the PRO-XTEN platform and strengthens liquidity. Management also sounded increasingly constructive on VIR-5500, pointing to proof of concept, FDA Fast Track, and plans to move toward multiple Phase III studies in 2027.
The biggest risks are that key clinical readouts are still ahead, so the investment case remains dependent on ECLIPSE data and future oncology execution. Management also acknowledged that VIR-5818’s study was revised after FDA feedback and is still incomplete, and it declined to share current VIR-5500 efficacy durability data. In hepatitis delta, the company still faces competition and will need to prove that its differentiated endpoints and convenience translate into a compelling commercial profile.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 79.2%
- Shares Outstanding
- 171.27M
- Float Shares
- 135.70M
of shares held by institutions
246 13F filers
Buy/sell ratio 3.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 22.45M | ▲ 1.77M |
| Arch Venture Management, LLC | 12.69M | 0 |
| Vanguard Group Inc | 12.55M | ▼ 250.44K |
| Vanguard Portfolio Management LLC | 12.02M | ▲ 529.14K |
| Sb Investment Advisers (Uk) Ltd | 10.95M | 0 |
| Gsk PLC | 8.55M | 0 |
| State Street Corp | 7.82M | ▼ 2.14M |
| Point72 Asset Management, L.P. | 6.77M | ▲ 1.11M |
| Vanguard Capital Management LLC | 6.45M | ▲ 60.80K |
| Dimensional Fund Advisors LP | 3.32M | ▲ 197.55K |
| Geode Capital Management, LLC | 3.02M | ▼ 328.65K |
| Mpm Bioimpact LLC | 2.81M | ▲ 2.81M |
Held by 365 ETFs
Biggest fund positions in VIR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 15, 26 | Sawaf Aziz | other | 150,000 |
| Nov 15, 26 | Sawaf Aziz | other | 75,000 |
| Nov 15, 26 | Sabatini Brent | other | 50,000 |
| Nov 2, 26 | de Verneuil Vanina | sell | 1,343 |
| Nov 3, 26 | de Verneuil Vanina | sell | 2,407 |
| Oct 27, 26 | Topalian Suzanne Louise | other | 9,462 |
| Oct 27, 26 | Topalian Suzanne Louise | other | 16,000 |
| Oct 27, 26 | Topalian Suzanne Louise | other | 4,731 |
| Oct 27, 26 | Topalian Suzanne Louise | other | 8,000 |
| Oct 27, 26 | Topalian Suzanne Louise | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VIR coverage
Recent articles, reports, and earnings notes.
No research on VIR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VIR report →Vir Biotechnology, Inc. (NASDAQ:VIR) Stock Has Average Target Price of $22.57
defenseworld.net · Nov 19
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
businesswire.com · Nov 12
Vir Biotechnology Announces Proposed Public Offering
businesswire.com · Nov 12
Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48
marketbeat.com · Nov 10
Vir Biotechnology: Fairly Valued After Phase 3 Success?
seekingalpha.com · Nov 10
Vir Biotechnology, Inc. (VIR) Discusses ECLIPSE 1 Topline Results and Expanded SOLSTICE Data Transcript
seekingalpha.com · Nov 9
Vir, A Gilead Rival, Shoots To Two-Year High On Its 'Clean Win' In Hepatitis D Treatment
investors.com · Nov 9
Wall Street Analysts Predict a 75.59% Upside in Vir Biotechnology (VIR): Here's What You Should Know
zacks.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.